Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Triple Negative Breast Cancer|Ovarian Cancer|Gastric Cancer|Colorectal Cancer|Glioblastoma|Biliary Tract Cancers|Pancreatic Cancer
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib
Sponsor: Merck Sharp & Dohme LLC
Collaborators: Eisai Inc.